Clinical trials: Liver Carcinoma Resectable
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
The purpose of this study is to evaluate the impact of iparomlimab and tuvonralimab as preoperative neoadjuvant therapy on recurrence-free survival (RFS), along with its potential improvement in overall survival (OS), in patients…
- Trial name
- CCGLC-017 (NCT06954116)
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Partial hepatectomy
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tongji Hospital
Pancreatic Ductal Adenocarcinoma, Liver, Cancer of, Primary Resectable
Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery
The goal of this study is to assess the efficacy of intraoperative celiac plexus block (CPB) to reduce opioid consumption following laparoscopic hepato-pancreato-biliary surgery
- Trial name
- CEBOIDS (NCT06214533)
- Testing
- Ropivacaine 0.5%, Normal Saline
- Volunteers
- 60 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Liver Cancer
Vaccine Therapy in Treating Patients With Liver Cancer
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00022334
- Testing
- AFP
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Hepatocellular Carcinoma Non-resectable
Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma
Patients with hepatocellular carcinoma often die from intrahepatic disease because current treatment options are limited. Local treatment using 166Ho-radioembolization (166Ho-RE) offers a safe and effective treatment.
- Trial name
- iHEPAR (NCT05114148)
- Testing
- Holmium-166 radioembolization
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- UMC Utrecht
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, oxaliplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00304135
- Testing
- cisplatin, gemcitabine hydrochloride, oxaliplatin
- Where
- 20 sites in France
- Volunteers
- 34 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Carcinoma, Hepatocellular
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC.
- Trial name
- NCT05908786
- Testing
- Atezolizumab, Bevacizumab, Tiragolumab
- Where
- 14 sites in United States, Austria and 4 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Hepatocellular, Metastatic Colorectal Cancer
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
- Trial name
- VEROnA (NCT03291379)
- Testing
- BTG-002814
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Boston Scientific Corporation
Perihilar Cholangiocarcinoma
LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)
LITALHICA is a prospective non-randomized study aimed at exploring the outcome of liver transplantation in selected patients with unresectable perihilar cholangiocarcinoma (pCCA) after treatment with standard of care…
- Trial name
- LITALHICA (NCT06125769)
- Testing
- Liver transplantation
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda Sanitaria Ospedaliera
Resectable Hepatocellular Carcinoma
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
This phase II trial studies the effect of nivolumab and ADI-PEG 20 before surgery in treating patients with liver cancer that can be removed by surgery (resectable).
- Trial name
- NCT04965714
- Testing
- Nivolumab, Pegargiminase, Resection
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)
This Phase I/II trial will evaluate the safety and activity of chemo-radiotherapy comprising a regimen of Sorafenib chemotherapy plus SIR-Spheres yttrium-90 microspheres (chemo-radiotherapy, also known as "chemo-SIRT"), for…
- Trial name
- NCT00712790
- Testing
- Sorafenib, SIR-Spheres
- Where
- 5 sites in Burma, Malaysia and 2 more
- Volunteers
- 35 people
- Sponsor
- Singapore Clinical Research Institute
Liver Carcinoma Resectable
Trans-parenchymal Compressing Suture in Major Liver Resection
Non-anatomical liver resection with appropriate resection margin was regarded as a potential curative treatment for selected major hepatic carcinoma due to preserving maximal normal liver, especially in cirrhotic patients.
- Trial name
- NCT03215290
- Testing
- TCS
- Volunteers
- 382 people
- Sponsor
- Tongji Hospital
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma
This research is being done to find how soon the liver cancer may come back and whether proteins or genes in tumor, blood or urine can give us clues of early recurrence.
- Trial name
- NCT00282100
- Testing
- Gefetinib (Iressa)
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Tan Tock Seng Hospital
Hepatocellular Carcinoma
HR Combined With FOLFOX4 for HCC With PVTT
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most frequent cause of cancer death worldwide. Hepatic resection (HR) is the conventional ''curative'' treatment for HCC.
- Trial name
- NCT02452853
- Testing
- HR, FOLFOX4
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer
Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers
This is a phase II, open-label, prospective single-centered study. Subjects who meet the inclusion/exclusion criteria will be allocated to appropriate cohorts: 1) gastric cancer, 2) esophageal cancer and 3) hepatocellular…
- Conditions
- Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer, Subjects With Resectable Liver Cancer
- Trial name
- NeoChance (NCT04196465)
- Testing
- IMC-001
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Asan Medical Center
Hepatocellular Carcinoma, Chemotherapy Effect
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
The goal of this clinical trial is to compare HAIC concurrently with sequentially combined with targeted and immunotherapies in terms of efficacy and safety in patients with potentially resectable intermediate and advanced HCC…
- Conditions
- Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
- Trial name
- HAIC (NCT06041477)
- Testing
- Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Concurrent Lenvatinib, Concurrent PD-1 antibody
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Sun Yat-sen University
HCC - Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide and ranks the third on the incidence of cancer-related death. There are more than 500000 new cases diagnosed annually worldwide.
- Trial name
- NCT07305428
- Testing
- Stereotactic Body Radiation Therapy followed by Immunotherapy
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Hepatocellular Carcinoma Non-resectable
The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
To investigate the safety and efficacy of deferoxamine (DFO) combined with conventional transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT03652467
- Testing
- Conventional TACE, Deferoxamine and conventional TACE
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jinan Military General Hospital
Colorectal Cancer Metastatic
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
This study is a randomized, multi-center study that will compare the efficacy and safety of selective internal radiation therapy (SIRT) using SIR-Spheres microspheres plus a standard chemotherapy regimen of FOLFOX6m versus…
- Trial name
- FOXFIREGlobal (NCT01721954)
- Testing
- FOLFOX6m, SIR-Spheres microspheres
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 209 people
- Sponsor
- Sirtex Medical
Hepatocellular Carcinoma Non-resectable
Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the established standard first-line systemic treatment for unresectable…
- Trial name
- ProtonAB (NCT06133062)
- Testing
- Atezolizumab, Bevacizumab, Proton radiotherapy
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital